ArticleBMJ open respiratory research2017

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.

Kevin R Flaherty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.